Drug Profile
AZD 7268
Alternative Names: AZD7268Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antidepressants; Anxiolytics
- Mechanism of Action Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 27 Jan 2011 Discontinued - Phase-I for Depression in Japan (PO)
- 27 Jan 2011 Discontinued - Phase-II for Depression in USA (PO)
- 13 Mar 2010 AstraZeneca completes enrolment in its phase II trial for Depression in USA